{rfName}
In

Indexed in

License and use

Icono OpenAccess

Citations

83

Altmetrics

Grant support

This research has been funded by grants from the Instituto de Salud Carlos III (FIS grant PI16/01296 and PFI17/00143), a grant from GETECCU (Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) and MSD. Funding agencies had no role in the study design, in the writing of the manuscript or in the decision to submit for publication.

Analysis of institutional authors

Castano-Milla, CarlosAuthor

Share

Publications
>
Article

Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

Publicated to:Journal Of Clinical Medicine. 10 (13): 2885- - 2021-07-01 10(13), DOI: 10.3390/jcm10132885

Authors: Chaparro, Maria; Garre, Ana; Nunez Ortiz, Andrea; Diz-Lois Palomares, Maria Teresa; Rodriguez, Cristina; Riestra, Sabino; Vela, Milagros; Manuel Benitez, Jose; Fernandez Salgado, Estela; Sanchez Rodriguez, Eugenia; Hernandez, Vicent; Ferreiro-Iglesias, Rocio; Diaz, Angel Ponferrada; Barrio, Jesus; Maria Huguet, Jose; Sicilia, Beatriz; Dolores Martin-Arranz, Maria; Calvet, Xavier; Ginard, Daniel; Alonso-Abreu, Inmaculada; Fernandez-Salazar, Luis; Varela Trastoy, Pilar; Rivero, Montserrat; Vera-Mendoza, Isabel; Vega, Pablo; Navarro, Pablo; Sierra, Monica; Luis Cabriada, Jose; Aguas, Mariam; Vicente, Raquel; Navarro-Llavat, Merce; Echarri, Ana; Gomollon, Fernando; Guerra del Rio, Elena; Pinero, Concepcion; Jose Casanova, Maria; Spicakova, Katerina; Ortiz de Zarate, Jone; Torrella Cortes, Emilio; Gutierrez, Ana; Alonso-Galan, Horacio; Hernandez-Martinez, Alvaro; Miguel Marrero, Jose; Lorente Poyatos, Rufo; Calafat, Margalida; Marti Romero, Lidia; Robledo, Pilar; Bosch, Orencio; Jimenez, Nuria; Esteve Comas, Maria; Maria Duque, Jose; Fuentes Coronel, Ana Maria; Josefa Sampedro, Manuela; Sese Abizanda, Eva; Herreros Martinez, Belen; Pozzati, Liliana; Fernandez Rosaenz, Hipolito; Crespo Suarez, Belen; Lopez Serrano, Pilar; Lucendo, Alfredo J; Munoz Vicente, Margarita; Bermejo, Fernando; Ramirez Palanca, Jose Joaquin; Menacho, Margarita; Carmona, Amalia; Camargo, Raquel; Torra Alsina, Sandra; Maroto, Nuria; Nerin de la Puerta, Juan; Castro, Elena; Marin-Jimenez, Ignacio; Botella, Belen; Sapina, Amparo; Cruz, Noelia; Forcelledo, Jose Luis F; Bouhmidi, Abdel; Castano-Milla, Carlos; Opio, Veronica; Nicolas, Isabel; Kutz, Marcos; Abraldes Bechiarelli, Alfredo; Gordillo, Jordi; Ber, Yolanda; Torres Dominguez, Yolanda; Novella Duran, Maria Teresa; Rodriguez Mondejar, Silvia; Martinez-Cerezo, Francisco J; Kolle, Lilyan; Sabat, Miriam; Ledezma, Cesar; Iyo, Eduardo; Roncero, Oscar; Irisarri, Rebeca; Lluis, Laia; Blazquez Gomez, Isabel; Maria Zapata, Eva; Jose Alcala, Maria; Martinez Pascual, Cristina; Montealegre, Maria; Mata, Laura; Monrobel, Ana; Hernandez Camba, Alejandro; Hernandez, Luis; Tejada, Maria; Mir, Alberto; Luisa Galve, Maria; Soler, Marta; Hervias, Daniel; Antonio Gomez-Valero, Jose; Barreiro-de Acosta, Manuel; Rodriguez-Artalejo, Fernando; Garcia-Esquinas, Esther; Gisbert, Javier P

Affiliations

Abstract

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31-56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.

Keywords

Biologic eraCrohn's diseaseCrohns-diseaseCrohn’s diseaseDiagnostic delayEpidemiologyEvidence-based consensusIncidenceInflammatory bowel diseasePrevalenceUlcerative colitis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Clinical Medicine due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 2.85. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 27.22 (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-06, the following number of citations:

  • WoS: 57
  • Europe PMC: 26
  • OpenCitations: 52

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-06:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 251.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 246 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 175.38.
  • The number of mentions on the social network Facebook: 2 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 31 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France.